mitoTALEN reduces the mutant mtDNA load in neurons

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Mitochondrial DNA (mtDNA) mutations are a common cause of severe encephalopathies.
• Most mtDNA defects occur in a heteroplasmic state, complicating treatment.
• Current therapeutic strategies for mtDNA-related neurological disorders are limited.

Purpose of the Study:

• To investigate the efficacy of mitochondrial-targeted TALEN (mitoTALEN) in selectively eliminating mutant mtDNA within the CNS.
• To assess the therapeutic potential of mitoTALEN for treating heteroplasmic mtDNA mutations causing encephalopathies.

Main Methods:

• Utilized a murine model with a heteroplasmic mutation in the mitochondrial tRNA alanine gene (m.5024C>T).
• Employed adeno-associated virus serotype PHP.eB (AAV-PHP.eB) for efficient neuronal delivery.
• Expressed mitoTALEN under a neuron-specific synapsin promoter for targeted gene editing in the CNS.

Main Results:

• Achieved effective transduction of most CNS regions.
• Demonstrated a significant reduction in mutant mtDNA levels.
• Observed an increase in mitochondrial tRNA alanine levels, counteracting the mutation's effect.

Conclusions:

• Mitochondrial-targeted gene editing is a viable strategy for reducing CNS-mutant mtDNA *in vivo*.
• This approach shows promise for the development of future clinical trials targeting mitochondrial encephalopathies.